IL158615A0 - Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome - Google Patents

Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome

Info

Publication number
IL158615A0
IL158615A0 IL15861502A IL15861502A IL158615A0 IL 158615 A0 IL158615 A0 IL 158615A0 IL 15861502 A IL15861502 A IL 15861502A IL 15861502 A IL15861502 A IL 15861502A IL 158615 A0 IL158615 A0 IL 158615A0
Authority
IL
Israel
Prior art keywords
acute
treatment
factor vii
respiratory distress
distress syndrome
Prior art date
Application number
IL15861502A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL158615A0 publication Critical patent/IL158615A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15861502A 2001-05-02 2002-05-01 Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome IL158615A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100692 2001-05-02
PCT/DK2002/000279 WO2002087605A2 (en) 2001-05-02 2002-05-01 Modified fvii in treatment of ards

Publications (1)

Publication Number Publication Date
IL158615A0 true IL158615A0 (en) 2004-05-12

Family

ID=8160467

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15861502A IL158615A0 (en) 2001-05-02 2002-05-01 Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome

Country Status (12)

Country Link
US (1) US20040033200A1 (zh)
EP (1) EP1385535A2 (zh)
JP (1) JP2004527554A (zh)
KR (1) KR20040094288A (zh)
CN (1) CN1522151A (zh)
AU (1) AU2002338487A1 (zh)
CA (1) CA2445811A1 (zh)
HU (1) HUP0304050A3 (zh)
IL (1) IL158615A0 (zh)
PL (1) PL366564A1 (zh)
RU (1) RU2003134701A (zh)
WO (1) WO2002087605A2 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235209A9 (en) * 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
EP1200116B1 (en) 1999-07-14 2008-10-15 Novo Nordisk Health Care AG USE OF FVIIa OR A TISSUE FACTOR AGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS
EP1644039B1 (en) * 2003-06-19 2014-10-01 Genentech, Inc. Compositions and methods for treating coagulation related disorders
ATE547519T1 (de) 2003-09-09 2012-03-15 Novo Nordisk Healthcare Ag Gerinnungsfaktor-vii-polypeptide
US8563511B2 (en) * 2004-10-06 2013-10-22 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
AU2006273696B2 (en) * 2005-06-24 2012-08-30 Drugrecure Aps Airway administration of activated protein C in inflammatory conditions affecting the respiratory tract
WO2009014633A1 (en) * 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
US8251876B2 (en) * 2008-04-22 2012-08-28 Hill-Rom Services, Inc. Breathing exercise apparatus
US9180271B2 (en) 2012-03-05 2015-11-10 Hill-Rom Services Pte. Ltd. Respiratory therapy device having standard and oscillatory PEP with nebulizer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5997864A (en) * 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
JP3459416B2 (ja) * 1991-02-28 2003-10-20 ザイモジェネティクス，インコーポレイティド 修飾されたファクター▲ｖｉｉ▼
CA2380633A1 (en) * 1999-08-06 2001-02-15 Genentech, Inc. Peptide antagonists of factor viia
CN1606452A (zh) * 2001-12-21 2005-04-13 诺沃娜第克公司 修饰的因子ⅶ多肽的液体组合物

Also Published As

Publication number Publication date
HUP0304050A3 (en) 2005-12-28
WO2002087605A2 (en) 2002-11-07
EP1385535A2 (en) 2004-02-04
US20040033200A1 (en) 2004-02-19
AU2002338487A1 (en) 2002-11-11
CN1522151A (zh) 2004-08-18
RU2003134701A (ru) 2005-03-27
WO2002087605A3 (en) 2003-01-03
PL366564A1 (en) 2005-02-07
HUP0304050A2 (hu) 2004-03-29
JP2004527554A (ja) 2004-09-09
KR20040094288A (ko) 2004-11-09
CA2445811A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
EP1699514A4 (en) MECHANICAL VENTILATION FOR BREATHING IN SLEEP
AU4579401A (en) Lung treatment apparatus
AU2003264282A1 (en) Phenethanolamine derivatives and their use in the treatment of respiratory diseases
IL150027A0 (en) Carbon dioxide enhancement of inhalation therapy
EE200400059A (et) Diarüültsükloalküülderivaadid, nende kasutamine ravimite valmistamiseks ning neid sisaldav ravim
HK1076686A1 (en) Smoking article and use thereof
EP1701756A4 (en) MACRO CONTROL OF THE TREATMENT OF BREATHING IN SLEEP
IL171972A0 (en) Compositions and methods for treatment of severe acute respiratory syndrome(sars)
PL387118A1 (pl) Kapsułki do inhalacji zawierające tiotropium i ich zastosowanie
SI1530466T1 (sl) Uporaba nintedaniba za zdravljenje pljučne fibroze
IL158615A0 (en) Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome
EP1575582A4 (en) COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODYSPLASIC SYNDROME
GB0004531D0 (en) The treatment of respiratory diseases
AU2003232148A8 (en) A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
EP1448185A4 (en) TREATMENT OF ASTHMA, CHRONIC OBSTRUCTIVE LUNG DISEASES AND / OR OTHER RESPIRATORY PROBLEMS
IL164078A0 (en) Treatment of lung disorder
EE200300513A (et) Piperasinoderivaadid, nende kasutamine hingamisteede haigusnähte leevendavate ravimite valmistamiseks ning neid sisaldavad ravimid
IS5755A (is) Notkun hreinljósvirks (-) norkisapríðs við meðhöndlun á öndunarstöðvun, lotugræðgi og öðrum meinum
EP1450831A4 (en) PROCESS FOR TREATMENT IN SITU IN THE LUNGS OF MAMMALS
AU2002231283A1 (en) Use of p38 inhibitors for the treatment of smoke inhalation
SI1216047T1 (sl) Kombinacija loteprednola in agonistov beta2-adrenoceptorja in njena uporaba za zdravljenje bronhialne astme
NO996060D0 (no) Pusteapparat for behandling av soevnapne
AU2003260033A1 (en) Methods of treating acute respiratory distress syndrome
DE60022070D1 (de) Verwendung von stickstoffoxid zur behandlung von atemwegs-verengungen
IL172528A0 (en) Surface treatment of sars-infected lungs